A December 10th news release from PR Newswire:TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.
To read the entire article, please click here.The annual meeting of the American Psychiatric Association is the year's largest psychiatry event. This year's conference in San Francisco indicated that long-acting depot versions of atypical antipsychotics continue to prove useful tools in the treatment of schizophrenia. In addition, new potential market entrants reported mixed data from new oral antipsychotics.
Although the majority of antipsychotics are now broadly used across most psychiatric conditions, the schizophrenia market continues to attract attention from developers of both novel antipsychotics and new formulations aimed at addressing the major unmet need of compliance.
The long-dosing regimen and intramuscular administration of long-acting injectable depot formulations of atypical antipsychotics results in a greater transparency of compliance. Eli Lilly presented new data for Zypadhera (olanzapine long-acting injection), as it continues to seek US approval and enter the market that Johnson & Johnson (J&J) has pioneered through Risperdal Consta (risperidone long-acting injection).
Data from new oral atypical antipsychotics were also presented. Vanda followed up the recent surprise approval of oral Fanapt (iloperidone) by presenting two posters detailing comparative data. Dainippon Sumitomo, meanwhile, provided delegates the first chance to see Phase III data for lurasidone.
